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Abstract 
Aβ plaques are one of the two lesions in the brain that define the neuropathological diagnosis of Alzheimer’s 
disease. Plaques are highly diverse structures; many of them include massed, fibrillar polymers of the Aβ pro-
tein referred to as Aβ-amyloid, but some lack the defining features of amyloid. Cellular elements in ‘classical’ 
plaques include abnormal neuronal processes and reactive glial cells, but these are not present in all plaques. 
Plaques have been given various names since their discovery in 1892, including senile plaques, amyloid plaques, 
and neuritic plaques. However, with the identification in the 1980s of Aβ as the obligatory and universal com-
ponent of plaques, the term ‘Aβ plaques’ has become a unifying term for these heterogeneous formations. 
Tauopathy, the second essential lesion of the Alzheimer’s disease diagnostic dyad, is downstream of Aβ-
proteopathy, but it is critically important for the manifestation of dementia. The etiologic link between Aβ-
proteopathy and tauopathy in Alzheimer’s disease remains largely undefined. Aβ plaques develop and propa-
gate via the misfolding, self-assembly and spread of Aβ by the prion-like mechanism of seeded protein aggrega-
tion. Partially overlapping sets of risk factors and sequelae, including inflammation, genetic variations, and var-
ious environmental triggers have been linked to plaque development and idiopathic Alzheimer’s disease, but 
no single factor has emerged as a requisite cause. The value of Aβ plaques per se as therapeutic targets is un-
certain; although some plaques are sites of focal gliosis and inflammation, the complexity of inflammatory bi-
ology presents challenges to glia-directed intervention. Small, soluble, oligomeric assemblies of Aβ are enriched 
in the vicinity of plaques, and these probably contribute to the toxic impact of Aβ aggregation on the brain. 
Measures designed to reduce the production or seeded self-assembly of Aβ can impede the formation of Aβ 
plaques and oligomers, along with their accompanying abnormalities; given the apparent long timecourse of 
the emergence, maturation and proliferation of Aβ plaques in humans, such therapies are likely to be most 
effective when begun early in the pathogenic process, before significant damage has been done to the brain. 
Since their discovery in the late 19th century, Aβ plaques have, time and again, illuminated fundamental mech-
anisms driving neurodegeneration, and they should remain at the forefront of efforts to understand, and there-
fore treat, Alzheimer’s disease. 
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1. Aβ, amyloid, and Alzheimer’s 
disease 
The most striking and yet still enigmatic 
pathologic features of Alzheimer’s disease (AD) are 
lesions known for over a century as senile plaques - 
microscopic anomalies in the parenchyma of the 
brain consisting of an abnormal accumulation of 
protein decorated by various molecules, and often 
including dystrophic neuronal processes and reac-
tive glial cells (Figure 1). Although plaques are a 
frequent feature of the senescent brain and, when 
particularly numerous, an obligatory diagnostic 
marker of AD [1], the identity of the principal pro-
tein in the plaque core remained unknown until the 
1980s. Then, Glenner and Wong established a par-
tial amino acid sequence of the protein in cerebral 
amyloid angiopathy (CAA) from patients with AD 
and Down syndrome [2, 3], and Masters and Bey-
reuther [4, 5] determined that the same protein is a 
key component of plaques. Initially referred to as 
the β protein, A4, or β/A4, the protein now is 
commonly designated Aβ [6]. Collectively, these 
lesions are increasingly referred to as Aβ plaques 
(see Section 3). 
1.1 Aβ 
Aβ is a cleavage product of the Aβ-precursor 
protein (APP), a 695–770 amino acid, single mem-
brane-spanning protein that is strongly expressed 
in the nervous system [7, 8]. Aβ is generated mainly 
in endosomes, and its release into the extracellular 
space is influenced by synaptic activity [9]. To pro-
duce Aβ, APP is sequentially cleaved by the en-
zymes β-secretase [or β-amyloid cleaving enzyme 
(BACE)] and γ-secretase [8], resulting in Aβ proteins 
that are most often 40 or 42 amino acids in length 
(‘Aβ40’ and ‘Aβ42’), although many C-terminally 
and N-terminally variant and/or chemically modi-
fied Aβ fragments also occur [7, 10-16]. Different 
lengths of Aβ can derive from their differential ex-
cision from APP by secretases or from post-
translational trimming of Aβ by exopeptidases [10]. 
Potential post-translational chemical modifications 
of Aβ include pyroglutamylation, racemization, 
isomerization, oxidation, phosphorylation, N-
homocysteinylation, nitration, and glycosylation 
[11, 17-19] (see also Section 7, below). How post-
translational modifications influence the process of 
protein aggregation in general remains poorly un-
derstood [20, 21]. 
 
 
Figure 1. 'Classical' Aβ (senile) plaques in the cortex of persons who had died with Alzheimer's disease (AD). Left, a plaque stained with 
the Naoumenko-Feigin silver method and periodic acid-Schiff (PAS) counterstain; an amyloid core (dark pink) is surrounded by profuse 
abnormal neurites (black). Right, a plaque immunostained with antibody 4G8 to the Aβ protein (brown) along with a Nissl counterstain 
(blue); glial nuclei are visible in the region between the plaque core and outer corona, and within and surrounding the corona. Bar = 
20μm for both panels. 
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Aβ40 is the isoform of Aβ that is most abun-
dantly generated by neurons, but two C-terminal 
hydrophobic residues in Aβ42 augment its tenden-
cy to self-assemble into amyloid [7, 22]. As a result, 
more plaques are immunoreactive for Aβ42 than 
for Aβ40 (Figure 2), although the relative amounts 
of plaques stained for Aβ40 and Aβ42 vary.  
 
 
Figure 2. Adjacent cortical tissue sections from an AD patient, 
immunostained with antibodies R398 to Aβ42 (top) and R361 
to Aβ40 (bottom). Two of the plaques that are present in both 
sections are denoted by arrows. Asterisks mark a blood vessel 
for reference. Bar = 100μm. 
 
Unlike plaques, cerebral Aβ-amyloid angiopa-
thy (Aβ-CAA) in large vessels is more consistently 
positive for Aβ40, though Aβ42 also is generally 
present [23]. The staining patterns of the two 
isoforms differ in capillary Aβ-CAA compared to 
large-vessel Aβ-CAA [24, 25], and in the vessel wall 
compared to the diffuse Aβ that sometimes ex-
tends from the wall into the surrounding paren-
chyma (dyshoric amyloid angiopathy) [25, 26]. The 
mechanisms governing the ontogeny of plaques 
and Aβ-CAA also probably differ to some extent 
(see Section 5.3).  
In addition to plaques and amyloid angiopa-
thy, Aβ multimerizes into a range of oligomeric 
species [27, 28] that can interact with cells and 
impair brain function [27, 29-35]. Oligomers appear 
to be an important intermediate step in the assem-
bly of polymeric amyloid of all types [20]. Compari-
son of subjects expressing AD-type dementia to 
nondemented subjects with high Aβ plaque pathol-
ogy, the amount of oligomeric Aβ correlates more 
strongly with cognitive decline than does the num-
ber of plaques per se [36]. Experimental studies 
indicate that Aβ plaques include abundant oligo-
mers [36, 37], and that some plaques shed toxic 
oligomers into the surrounding parenchyma [37-
39]. Aβ42-oligomers have been shown to arise 
from secondary nucleation on Aβ-amyloid fibrils 
during protein aggregation, directly linking them to 
the process of amyloidogenesis [34]. At least some 
Aβ-oligomers are particularly potent seeds for the 
formation of Aβ plaques [40, 41], although whether 
there are seed-active oligomers that differ from 
toxic oligomers, as has been found for prions [42], 
is unknown. The relationship between Aβ-
oligomers and the diverse plaque types [31, 33, 38] 
in the human brain - e.g., dense-core vs diffuse - 
also is an issue that remains incompletely defined. 
Indeed, owing to their dynamicity and heterogenei-
ty, the analysis of oligomers as they occur in living 
systems is technically challenging [20] (see also 
Benilova et al. [43] for a critique of oligomers as 
toxic agents). Regardless of the relative contribu-
tion of Aβ-oligomers and amyloid fibrils to disease, 
both of these multimeric states denote the pres-
ence of an abnormal condition in the brain, i.e., the 
misfolding and accumulation of the Aβ protein.  
Aβ has assumed a prominent position in Alz-
heimer research because all identified risk factors 
for AD increase its quantity and/or tendency to 
aggregate [33, 44, 45]. Most notably, mutations in 
APP and the presenilins (components of the γ-
secretase complex) [22] are the only known auto-
somal dominant causes of AD, and a superfluous 
APP gene due to trisomic chromosome 21 in Down 
Syndrome frequently leads to early-onset AD [35, 
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46, 47]. Furthermore, a rare mutation that substi-
tutes a threonine for alanine (A673T) at position 2 
of Aβ lowers both the production of Aβ [48] and its 
propensity to aggregate [49]; this mutation is asso-
ciated with a reduced risk of manifesting AD [48] 
and possibly parenchymal plaques as well [50]. 
Contrariwise, when a valine replaces alanine at 
position 2 (A673V), Aβ generation is increased, and 
the protein is more prone to aggregate, resulting in 
an autosomal recessive form of AD [51]. Thus, 
there is little doubt that Aβ is intimately involved in 
the pathogenesis of AD, although many questions 
remain about how plaques per se participate in the 
neurodegenerative process. 
1.2 Amyloid 
A persistent source of misunderstanding re-
garding the role of Aβ in AD is the common use of 
the generic term ‘amyloid’ to refer to the protein 
Aβ. In pathology, amyloid refers to ‘mainly extracel-
lular tissue deposits of protein fibrils, recognized by 
certain properties, such as green-yellow birefrin-
gence after staining with Congo red’ [6] (for histori-
cal considerations of amyloid, see [20, 52-55], and 
for more on the definition of amyloid see [20, 56, 
57]. Amyloid can arise from over 30 different pro-
teins in various parts of the body in different hu-
man diseases [6, 58]. Hence, ‘Aβ’ the molecule and 
‘amyloid’ the fibrillar mass are not synonymous. Aβ 
refers exclusively to the protein that, when aggre-
gated into distinctive fibrils, constitutes the specific 
type of amyloid that most commonly accumulates 
in the aging brain. 
The formation of amyloid involves the misfold-
ing and self-assembly of a particular protein into 
filamentous structures with a distinctive cross-β 
architecture that is stabilized by a ‘steric zipper’ 
molecular motif [20, 59]. The misfolded protein has 
two notable characteristics that contribute to its 
amyloidogenicity: 1) it compels unfolded molecules 
of the same protein to similarly misfold by means 
of permissive templating [60]; and 2) the β-sheets 
in separate molecules hydrogen-bond to one an-
other to form stable, filiform polymers with the β-
sheets oriented perpendicular to the long axis of 
the polymer [59]. In this way, the misshapen pro-
teins both corrupt and capture like proteins, which 
stack into protofilaments that wind together to 
build long, non-branching fibrils that typically range 
from ~6 to 13 nm in diameter [54]. These fibrils are 
characteristic of amyloid in general [6]. Despite 
their shared cross-β backbone and similar appear-
ance by conventional transmission electron micros-
copy, however, amyloid fibrils are polymorphic at 
the molecular level [20, 61-68].  
 
 
Figure 3. An Aβ plaque (brown) alongside intracellular tau 
tangles (purple) in the cortex of an AD patient. Combined 
polyclonal antibodies R398+R361 to Aβ40+42 plus monoclonal 
antibody CP13 to hyperphosphorylated tau. Bar = 20μm. 
 
Although amyloid was long defined as an ex-
clusively extracellular substance [69-71], it is now 
recognized to occur intracellularly as certain types 
of inclusion [6, 20]. The tau protein that polymeriz-
es into neurofibrillary tangles - the second manda-
tory pathologic hallmark of AD (Figure 3) - has at-
tributes of amyloid [72]. Thus, the two lesions that 
characterize AD pathologically - plaques and tan-
gles - arise from two different proteins - Aβ and tau 
- both of which can misfold and self-assemble into 
amyloid.  
Despite genetic, biomarker and pathologic 
findings implicating aberrant Aβ in the initiation of 
AD [9, 33, 44], tauopathy is more strongly correlat-
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ed with cognitive decline than are plaques [73-78]. 
In the forebrain, tangles first appear in the medial 
temporal lobe [79, 80], but the dementia of AD is 
fully apparent only when tauopathy becomes se-
vere in much of the neocortex [1, 81], a process 
that is facilitated by the presence of Aβ pathology 
[9] (see also [82]). The precise nature of the mech-
anistic link between Aβ-proteopathy and tauopathy 
in AD, however, remains a critical unsolved prob-
lem [45, 83, 84].  
2. The discovery and early exploration 
of plaques 
The late 19th and early 20th centuries saw a 
profusion of new staining methods that selectively 
revealed various elements in cells and tissues [85]. 
Accordingly, the original depictions of plaques re-
flected what was disclosed by histologic stains and 
viewed with the light microscope. In 1892, Paul 
Blocq and Georges Marinesco at the Salpêtrière 
Hospital in Paris reported microscopic ‘amas ronds’ 
(‘round clusters’, or ‘round heaps’) or ‘nodules de 
sclérose névroglique’ (‘nodules of neuroglial sclero-
sis’) in the brains of older epileptic patients [86].1 
This report is generally considered to be the first 
unambiguous identification of plaques in the se-
nescent brain [81, 87]. In 1898, Emil Redlich pub-
lished evidence linking plaques to dementia [88]; in 
the brains of three elderly subjects, two of whom 
had died with clinically confirmed dementia, Red-
lich described the structures as consisting of a core 
of uncertain substance along with surrounding 
astrocytes (‘Spinnenzellen’) and their processes. 
Because they resembled millet seeds under the 
microscope, he referred to these collective lesions 
as ‘miliary sclerosis’ (‘miliare Sklerose’). Notably, 
Redlich also dubbed them ‘plaques’, a term that 
was expanded to ‘senile plaques’ by Simchowicz in 
1911 [89]. Furthermore, Redlich noted that some 
smaller lesions consisted of fine fibers with a cot-
ton-like appearance [88], anticipating the use of 
                                                          
1 ‘Il existe de plus, disséminés dans les diverses couches de l’écorce, de 
petits amas ronds d’un diamètre de 60 µ environ, se distinguant du 
reste du tissu par une coloration beaucoup plus intense, à contours 
réguliers. Ils apparaissent ainsi, parsemant discrètement le fond des 
préparations, d’une structure vaguement pointillée, ce pourquoi il est 
permis de considérer quelques-uns d’entre eux, au moins, comme de 
véritables nodules de sclérose névroglique (?).’ (Question mark is in 
the original) 
the term ‘cotton-wool plaques’ to depict certain 
types of deposit today [90-94].  
Although Alois Alzheimer is often credited 
with instigating the burst of scientific analyses of 
plaques with his 1906 conference presentation in 
Tübingen (published in 1907) [95], his report was 
brief, and plaques (‘miliary foci’) were only superfi-
cially mentioned.2 He did not issue his first detailed 
histopathologic examination of plaques until 1911 
[96]. In fact, along with Redlich [88], a good case 
can be made that Oskar Fischer deserves the credit 
for initiating the modern histopathologic analysis of 
dementia with a comprehensive series of reports 
published in 1907, 1910, and 1912 [87]. Several 
other researchers contributed to the literature on 
plaques during this period, including, among oth-
ers, Miyake [97], Lafora [98], Bonfiglio [99], Hübner 
[100], Perusini [101], Fuller [102], Bielschowsky 
[103], Barrett [104], Simchowicz [105] and 
Marinesco and Minea [106] (see also Christen [107] 
for a brief historical perspective on this period of 
research into what we now call AD).  
Both Alzheimer and Fischer excelled in their 
analysis of plaques by implementing a silver-based 
staining method introduced by Max Bielschowsky 
[87] (see Braak and Braak [108] for a nice summary 
of the early development of silver stains).3 Alz-
heimer did, however, correctly anticipate the evo-
lution of neurology in his 1907 publication, in which 
he contended that the time had come to define 
neurologic diseases based on both their clinical and 
histologic characteristics [95].4 This view has a con-
temporary parallel in the call by an international 
                                                          
2 ‘Über die ganze Rinde zerstreut, besonders zahlreich in den oberen 
Schichten, findet man miliare Herdchen, welche durch Einlagerung 
eines eigenartigen Stoffes in die Hirnrinde bedingt sind. Er lässt sich 
schon ohne Färbung erkennen, ist aber Färbungen gegenüber sehr 
refractär.’ 
3 Many different silver stains have been developed to detect AD 
pathology. Each method selectively reveals certain elements in the 
plaques, and they are sometimes considered to be less sensitive than is 
immunostaining with antibodies to Aβ. Some silver stains, however, 
are exquisitely sensitive even to small, diffuse Aβ deposits, which have 
been recognized in AD tissue since the early 20th century (see, e.g., 
Marinesco and Minea [1912] [reference 106] and Cowe, A. [1915] 
[reference 508]). Note also Figure 23. 
4 ‘Es gibt ganz zweifellos viel mehr psychische Krankheiten, als sie 
unsere Lehrbücher aufführen. In manchen solchen Fällen wird dann 
eine spätere histologische Untersuchung die Besonderheit des Falles 
feststellen lassen. Dann werden wir aber auch allmählich dazu 
kommen, von den großen Krankheitsgruppen unserer Lehrbücher 
einzelne Krankeiten (sic) klinisch abzuscheiden und jene selbst klinisch 
schärfer zu umgrenzen.’ 
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group of experts for a biological, rather than syn-
dromic, definition of AD [109]. Furthermore, Alz-
heimer noted in 1911 the prevailing technical ina-
bility to identify the substance in the plaque core: 
‘... we have to consider the core of the plaque as an 
unorganized mass which emerges differently with 
different staining methods ... As Perusini and Fisch-
er have already explained, we are not at present 
able to identify this mass with any of the substanc-
es known in pathological anatomy’ (translation 
from [110]). In addition, Alzheimer highlighted the 
prominence of glial cells in the composition of 
plaques [96], a subject that has gained momentum 
in the 21st century, owing in part to the identifica-
tion of compelling, glia-related genetic risk factors 
for AD [111-115] (see Section 6.2).  
From the early 20th century on, researchers 
widely agreed that the main structural elements 
comprising plaques are abnormal neuronal pro-
cesses, altered glial cells, and a central, disordered 
mass of unidentified material. In a 1929 review, 
Macdonald Critchley [116] wrote that the ‘modern 
conception of the plaque is that of a reactionary 
change directed against a specific metabolic pro-
cess of a toxic nature’ (a description that, if we 
consider the material in the core to be the key toxic 
substance, resonates with leading 21st century 
concepts). 
Many pioneering scientists attempted to ex-
plain the origin and nature of plaques based on 
their interpretations of static images in selectively 
stained tissue sections. Not surprisingly, disagree-
ment was common (see, e.g., [99], [101], [102], 
[117]). Ferraro (1931) summarized this lack of con-
sensus: ‘...one group of investigators favors the 
theory that [the plaque] originates from nerve cells, 
another that it originates from neuroglial elements, 
another from axis cylinders, and still another, from 
the intercellular ground substance’ [118]. Soniat 
remarked in 1941 that ‘No less than twenty differ-
ent concepts concerning their origin have appeared 
in the literature’ [119]. As late as 1960, Liss wrote, 
citing three influential textbooks on pathology, that 
the ‘morphogenesis of senile plaques remains still 
an unsettled and controversial matter’ [120].  
A crucial question, and a source of much of 
the discord among researchers, was the nature of 
the plaque core - what does it consist of, how does 
it arise, what impact does it have, and what gov-
erns the proliferation of plaques in the brain? The 
answers to these questions would not begin to 
emerge for another half century. In fact, no com-
pelling conceptual insights immediately followed 
the initial flurry of histopathological investigations 
of plaques, which, ultimately, were hampered by 
limitations in the available methods [119, 121]. 
Beginning in the 1960s, theoretical and analyt-
ical advances accelerated; electron-microscopic 
studies showed that the mature plaque core con-
sists of amyloid fibrils structurally similar to those 
in corporeal amyloidoses [122, 123], and quantita-
tive analyses confirmed that plaque load in the 
brain is linked to dementia [124]. Most important, 
however, was the molecular decipherment of Aβ as 
the primary protein in cerebral amyloid by Glenner 
and Wong [2, 3] and Masters and colleagues [4]. 
The genetic insights and technical tools resulting 
from this discovery ultimately established Aβ as a 
critical player in the pathogenesis of AD, and the 
plaques that occur in normal aging and AD could, 
for the first time, be unified by a single, omnipres-
ent component - aberrant Aβ. 
3. Plaque nomenclature: The case for 
‘Aβ plaques’ 
The term ‘plaque’ (which historically has re-
ferred to a flat object such as a disk or tablet) was 
adopted by the medical community in the mid-to-
late late 1800s to designate patch-like abnormali-
ties such as atherosclerotic plaque or dental 
plaque.5 Redlich [88] used the term to describe 
carmine-stained densities (‘intensiv gefärbten 
Plaques’), and Simchowicz [105] added the modifi-
er ‘senile’ to denote their frequency in senescent 
brains, particularly in patients with senile dementia 
[89]. Most plaques in the brain (unlike dental or 
atherosclerotic plaque) are not planar (one excep-
tion being the band-like subpial deposits [see Fig-
ure 9]). Of course, spheroidal plaques appear dis-
                                                          
5 ‘plaque (Subject: Medicine and health): Any small patch or region of 
abnormal tissue within the body. See amyloid plaque, gliosis. [From 
French plaquer to plate, from Middle Dutch placken to beat metal].’ 
From: Oxford Dictionary of Word Origins:  
https://www.oxfordreference.com/view/10.1093/acref/97801995479
20.001.0001/acref-9780199547920  
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coid in histologic sections, and their apparent size 
and composition are influenced by the plane 
through which they are cut (Figure 4).  
Some of the designations for plaques derive 
from their staining characteristics. Following Divry’s 
discovery that certain plaques show amyloid-type 
birefringence after staining with the dye Congo red 
[125], the terms ‘congophilic plaques’ or ‘amyloid 
plaques’ became common. The term ‘argyrophilic 
plaques’ also has been employed, owing to their 
detectability by various silver-based staining meth-
ods [81]. Other labels such as ‘miliary plaques’, 
‘Drusen’,6 and ‘Redlich-Fischer plaques’ can be 
found in the earlier literature [116]. In 1972, 
Wisniewski and Terry introduced the term ‘neuritic 
plaques’ in recognition of the profusion of abnor-
mal neuronal processes that invest many plaques. 
With the identification of the Aβ protein in plaques, 
the term ‘Aβ plaques’ is increasingly common. For 
the following reasons, ‘Aβ plaques’ is recommend-
ed as the inclusive term that succinctly encom-
passes the multiplicity of these lesions under the 
umbrella of their shared feature - Aβ deposition:7 
1) Aβ is present in all of the plaques that are 
linked to ‘normal’ aging and AD, regardless of size, 
shape, aggregation state, location, or overall com-
position.  
2) The term ‘senile’ is vague and arbitrary, and 
not all plaques occur in ‘senile’ humans. Although 
Aβ plaques become more common at older ages, 
they can emerge in the 4th decade of life or earlier, 
especially in people with some autosomal domi-
nant forms of AD [126].8  
3) Plaques that are structurally similar to Aβ 
plaques occur in other neurodegenerative disor-
ders, yet these result from the misfolding and ag-
gregation of different proteins. Such plaque-
                                                          
6 Note that ‘Druse’ (‘geode’) differs from ‘Drüse’ (with Umlaut), which 
refers to a ‘gland’. 
7 Because ‘Aβ’ and ‘plaque’ are both nouns, they could be connected 
by a hyphen (Aβ-plaque). I have chosen not to include the hyphen (the 
‘open form’) in order to simplify usage. In some cases (such as Aβ-CAA 
& Aβ-oligomers), I have retained the hyphen for clarity. 
8 W.H. McMenemey opined in 1963: ‘...the structures first observed by 
Blocq & Marinesco (1892) and thought by them to be nodules of glial 
sclerosis were called by Simchowicz (1910) ‘senile plaques’ - an 
unfortunate choice of name for it has coloured our thinking for the 
past fifty years’ [reference 509]. 
forming proteins include the prion protein (PrP) in 
certain spongiform encephalopathies [127, 128], 
the ABri protein in Familial British Dementia [129, 
130], and the ADan protein in Familial Danish De-
mentia [131, 132].  
4) Not all Aβ deposits incorporate abnormal 
neurites, which often are sparse or absent in dif-
fuse plaques [133] including cotton-wool plaques 
[90, 93, 134] (see below). The term ‘neuritic 
plaques’ is suitable for the lesions that contain neu-
rites, but these are only a subset of the entire fami-
ly of Aβ plaques. 
5) The Aβ in plaques does not always meet all 
of the criteria for amyloid [6] (see Section 1.2). 
Many diffuse Aβ deposits in the aging brain do not 
show birefringence after staining with Congo red. 
In addition, large, cotton-wool Aβ plaques lacking 
amyloid cores are abundant in certain presenilin-1 
mutant cases of autosomal dominant AD [90, 91, 
93, 94, 134] and in some non-familial cases [92]. 
(The Aβ in non-amyloid plaques from some prese-
nilin-1 mutant cases is unusual in that it consists 
mostly of N-terminally truncated Aβ [94], as do 
diffuse deposits in the cerebellum in AD [135] and 
Down syndrome [135, 136]). The term ‘amyloid 
plaques’, like ‘neuritic plaques’, is appropriate for a 
subgroup of the lesions, but the universal constitu-
ent is Aβ, whether it is in the form of amyloid or 
not; hence, more precise designations of plaque 
subtypes would be, for example, ‘Aβ-amyloid 
plaques’ and ‘neuritic Aβ plaques’.  
Note that ‘diffuse plaques’ here refers to the 
fact that the Aβ accumulation is ‘widely spread or 
scattered; not concentrated’ [137], without consid-
eration of the nature of the Aβ deposits, e.g., 
thread-like or punctate. ‘Diffuse’ thus denotes only 
the characteristics of the Aβ deposits, and not the 
dysmorphic neurites or any other component of 
the plaques. Also, when analyzing Aβ plaques histo-
logically, it is useful to be cognizant of the plane of 
section, thickness of the tissue, and the limitations 
of a given staining protocol. Plaques are 3-
dimensional structures that, when large enough, 
are only partially captured in thin histologic sec-
tions (Figure 4). Furthermore, different stains re-
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Figure 4. A neuritic Aβ plaque in consecutive sections of the cortex from an AD patient; The core is evident in the left-hand image, 
whereas sections through the periphery (middle and right) reveal only neurites (black). Serial sections may be required to unequivocally 
identify plaque types (a technical caveat noted by, among others, Alzheimer [1911] [reference 96]). Naoumenko-Feigin (silver) and 
periodic-Schiff stains. Bar = 20 μm for all images. 
 
 
cognize different components of plaques. Conse-
quently, a comprehensive assessment of plaques 
requires their full reconstruction and the applica-
tion of suitable markers for potential components. 
In congruence with the trend to define AD ac-
cording to its molecular underpinnings [109], defin-
ing the plaques that occur in aging and AD based on 
their principal proteinaceous component unambig-
uously distinguishes them from similar lesions in 
other disorders. In addition, this molecularly 
grounded moniker explicitly specifies the attribute 
that defines these plaques as unique pathologic 
entities: the misfolding and abnormal accumulation 
of the Aβ protein. 
4. The anatomic distribution of Aβ 
plaques 
4.1 Histology 
Determination of the amino acid sequence of 
Aβ [2-4] prompted the development of sensitive 
and specific antibodies that have facilitated the 
investigation of the anatomic localization, structur-
al diversity, and biochemical composition of Aβ 
deposits in the brain. Aβ plaques become increas-
ingly frequent as age advances [80, 138], but they 
are especially numerous in AD patients.  
The anatomic distribution of Aβ plaques is var-
iable, and it differs both among individuals and 
among brain regions in a given person [139-141] 
(Figure 5). In general, association areas of the neo-
cortex are more vulnerable and/or affected earlier 
than are primary motor and sensory areas [140]. 
Aβ deposition is particularly profuse in the default 
mode network, an interconnected assemblage of 
brain regions that maintain vigorous metabolic 
activity when the brain is in an otherwise resting 
state [142]. The structure of Aβ plaques is influ-
enced in part by the architectonic characteristics of 
the areas in which they form [139, 143], but it is 
usual for several kinds of plaque to intermix within 
a given site (Figure 6). In the neocortex, the laminar 
distribution of diverse Aβ plaques can vary marked-
ly [140] (Figure 5). 
Based on an analysis of human brains with dif-
ferent degrees of plaque accumulation, a spatio-
temporal course of Aβ plaque formation has been 
proposed [19, 144, 145]. There is general agree-
ment that diffuse plaques are the earliest type to 
emerge, followed later by cored (amyloid) plaques 
[146]. According to Thal and colleagues, in the first 
phase of the process, diffuse Aβ plaques appear in 
the neo(iso)cortex; in the second phase, allocortex, 
the hippocampal formation and amygdala are af-
fected; in the third phase, plaques arise in the basal 
ganglia and diencephalon; in the fourth phase they 
appear in the midbrain and medulla oblongata; and 
in the fifth phase, the pons and cerebellum are 
affected [19, 144, 145] (Figure 7). These stages 
have been consolidated by Serrano-Pozo and col-
leagues [133] into an isocortical stage 1, allocorti-
cal/limbic stage 2, and subcortical stage 3. This gen- 
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Figure 5. Variation in Aβ deposition in adjacent cortical gyri 




Figure 6. Variable morphology of Aβ plaques in the cortex of 
an AD patient. Classical dense-cored plaques with the core-
space-corona pattern are in the upper left and lower right, and 
an irregular cloud of diffuse material is near the center, along 
with numerous very small patches. Antibody 4G8; Nissl coun-
terstain. Bar = 50μm. 
 
eral pattern of spread has been confirmed by a 
cross-sectional in vivo analysis of Aβ-amyloid depo-
sition profiles using Florbetapir-PET imaging [147]. 
Thus, in the end-stage of AD, most brain areas ex-
hibit at least some Aβ deposition. The spinal cord 
has been less studied; while it appears to be largely 
spared, plaques there have been reported in some 
instances [93, 148]. 
 
4.2. In vivo imaging 
At the turn of the 21st century, the first imag-
ing agents were introduced to detect amyloid in 
the living human brain via positron emission to-
mography [149, 150]. Jorge Barrio and colleagues 
introduced 2-(1-[[6-[(2-[18F]fluoroethyl) (methyl) 
amino]-2-naphthyl]]ethylidene) malononitrile ([18F] 
FDDNP), which binds to both Aβ-amyloid and tau 
tangles, and which has achieved some utility in 
diagnosing tauopathies [151-153]. A more Aβ-se- 
lective ligand, developed by William Klunk, Chester 
Mathis and colleagues, is 2-(4’-[11C]methylamino- 
phenyl)-6-hydroxybenzothiazole (Pittsburgh Com-
pound-B [PiB]) [149, 154]. Derived from the chemi-
cal structure of the histologic staining agent Thio-
flavin-T, PiB crosses the blood-brain barrier and 
binds with high affinity and selectivity to Aβ depos-
its in plaques and CAA [154].9 PiB (which is labeled 
with carbon-11), was followed by similar PET lig-
ands labeled with fluorine-18 (a radiolabel with a 
longer half-life than carbon-11): Florbetapir (Amy- 
vid) [155, 156], Florbetaben (Neuraceq) [157], and 
Flutemetamol (Vizamyl) [158].  
By assessing Aβ-amyloid load in living sub-
jects, these imaging agents have facilitated the 
differential diagnosis of AD and the longitudinal 
tracking of Aβ accumulation. They are particularly 
sensitive in detecting dense-core Aβ plaques, al-
though they also bind to some extent to Aβ-CAA 
and diffuse Aβ deposits [47, 159-161]. Histochemi-
cal analysis of fluorescently labeled (‘clicked’) PiB 
applied to AD tissue sections confirms the prefer-
ence of PiB at low concentration (100nM) for 
dense-core plaques [162]. Interestingly, PiB does 
not show significant high-affinity binding to Aβ-
amyloid deposits in aged nonhuman primates with 
substantial Aβ burden [163], even though the ami-
no acid sequence is identical to that of humans (see 
Section 10). (Note that binding of ligands can vary
                                                          
9 In the 1920s, Congo red was introduced as an in vivo diagnostic agent 
for non-cerebral amyloidosis. Following intravenous injection, the rate 
at which Congo red was cleared from the blood was thought to reflect 
amyloid burden in affected organs (the more amyloid to bind the dye, 
the more rapid its clearance from blood). For various reasons, the test 
never achieved widespread use (see Buxbaum and Linke [2012] 
[reference 52]). 
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Figure 7. The phases of Aβ plaque distribution in the brain [references 19, 145]; illustration courtesy of Dietmar Thal, KU Leuven. 
 
 
among humans; for example, a case of end-stage 
AD has been reported with extraordinarily high Aβ 
load, a predominance of Aβ40, and minimal high-
affinity binding of PiB [164]). Since neither AD-like 
tauopathy nor dementia has been reported in non-
human primates [165], comparative analysis of 
ligand binding could be useful in defining the vari-
ant molecular characteristics of Aβ deposits and 
their relationship to disease phenotype (see Sec-
tions 5.2 and 10). 
5. The variety of Aβ deposits 
5.1 Aβ plaques 
The histologic implementation of specific an-
tibodies in the 1980s firmly established that Aβ 
plaques in the brains of Alzheimer patients com-
prise a remarkable variety of morphologies [143, 
166-172]. Several modern classification schemes 
have been proposed (e.g., [143, 166, 173-176]), and 
while there is not universal agreement on some of 
the terms, Aβ plaques can be broadly categorized 
into amyloid plaques per se (with dense, con-
gophilic cores), and a range of more loosely orga-
nized deposits of myriad sizes, shapes, densities 
and locations [133] (Figures 5, 6, 8, 9). It is note-
worthy that different genetic mutations can be 
associated with particular predominant plaque 
morphologies, as well as the presence of CAA (see 
Alzforum for a list of Alzheimer-associated muta-
tions (https://www.alzforum.org/mutations). Note 
also that relatively few of the mutant forms of AD 
have been thoroughly scrutinized neuropathologi-
cally.  
Within the general categories of plaque struc-
ture, the Aβ-amyloid plaques are more or less 
spheroidal lesions that include ‘classical’ or ‘ma-
ture’ plaques and so-called ‘burned-out’ or ‘com-
pact’ plaques [177, 178]. Recently, a ‘coarse-grain’ 
plaque type with multiple small cores and a pre-
dominance of Aβ40 has been described in ad-
vanced AD cases, often in association with APOE4 
homozygosity and CAA [179]. Diffuse Aβ plaques 
are much more numerous than are amyloid 
plaques in the Alzheimeric brain [143] (Figures 6, 
8), and they span a range of compactness from 
vaguely Aβ-immunoreactive, Congo red-negative 
regions (e.g., ‘fleecy’ plaques [180]) to clusters of 
loose fibrillar material that sometimes are weakly 
congophilic [139, 166]. Ultrastructurally, some of 
these diffuse deposits have been shown to include 
amyloid fibrils [181-183], whereas others do not 
[183], the latter possibly representing a pre-
amyloid stage of Aβ aggregation [139]. 
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Figure 8. Small, often stellate Aβ deposits in the cortex of an AD patient. Some Aβ accumulates within glial cells, most likely astrocytes 
(right). Antibody 4G8; Nissl counterstain. Bars = 20μm. 
 
 
Diffuse Aβ plaques comprise very small, often 
stellate assemblies scattered about the parenchy-
ma (Figure 8), a sheet-like band of sometimes con-
fluent, sometimes patchy material in the subpial 
cortex (Figure 9), large ‘cotton-wool’ plaques, and 
very large ‘lake-like’ patches, including a distinctive 
cribriform deposit in the subicular complex [143, 
171, 176, 184] (Figure 9). Abnormal neurites gen-
erally are absent or sparse in diffuse deposits [139], 
and this includes the cotton-wool plaques that are 
characteristic of some advanced AD cases [90-94, 
134].  
Despite their abundance in the Alzheimeric 
brain, very small diffuse deposits have received 
remarkably little scientific attention [175]. These 
probably correspond to the small (~2μm diameter) 
‘Sternchen’ which Fischer in 1910 considered to be 
the first stage of plaque formation [185]. At least 
some of them appear to be related to astrocytes 
[175, 186] (Figure 8), but the absence of systematic 
research on these ubiquitous lesions currently pre-
cludes meaningful consideration of their involve-
ment in the proteopathic process. Similarly, the 
immunoreactivity of some vestigial (extracellular) 
neurofibrillary tangles with antibodies to Aβ [187-
194] (Figure 10) remains mechanistically unde-
fined.  
Certain types of Aβ plaque are typical of the 
brain compartments in which they develop, e.g., in 
the cerebellum, basal ganglia, or different cortical 
regions and laminae (see [139]). In the white mat-
ter, distinctive granular accumulations of Aβ [143] 
occur to varying degrees (Figure 11). These clusters 
consist of fibrillar Aβ lying outside of the axons, and 
they appear not to be associated with obvious 
tauopathy or other abnormalities of the axons 
themselves [143], although their functional signifi-
cance is largely unexplored.  
The core-space-corona arrangement of Aβ is a 
notable structural feature of classical Aβ plaques 
that was noted in several early investigations (re-
viewed in [116, 119, 120]). These subdivisions of 
plaques have been given various designations in 
the early literature, for instance Zentrum or Kern, 
Hof, Ring, etc.10 In tissue that has been im-
munostained for Aβ, classical Aβ plaques have a 
condensed core of Aβ-amyloid surrounded by an 
optically clear region with little Aβ, and then an 
outer corona of more diffuse Aβ [195] (see Figure 
1); the relatively clear intermediate space and the 
outer corona are occupied by neuronal and glial 
elements (which are considered in more detail in 
Section 6).  
                                                          
10 Fischer [1910] [reference 185] referred to the central core as the 
‘Morgenstern’ (morning star), and described the structure of one type 
of plaque thusly: ‘Auch hier ist ein zentraler Morgenstern, aus dem 
mehr oder weniger lange Büschel entspringen; der Fädchenring ist 
ziemlich weit vom Zentrum entfernt, so dass ein grosser Hof entsteht, 
der von den Strähnchen durchzogen wird’ 
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Figure 9. Band-like subpial Aβ (left) in neocortical layer 1 and presubicular lake-like Aβ (right) from two cases of AD. The subpial Aβ can 
be discontinuous, confluent, or punctate. Antibodies 4G8 (left) and 6E10 (right); Nissl counterstain. Bar = 100μm for both images. 
 
 
Viewed in the electron microscope, Aβ-
amyloid fibrils in the plaque core are densely 
packed and often bundled to form a patchy matrix, 
and viable cellular processes there are largely ab-
sent. The more loosely organized Aβ-amyloid 
sheaves in the space and corona interdigitate with 
cellular elements such as glial processes and neu-
rites (Figure 12; see also Figures 18 and 20). Em-
bedded in the fibrillar meshwork of amyloid in 
plaques, various small, spherical particles can be 
seen (Figure 13). The origin and significance of this 
material is obscure, but it could account for some 
of the non-Aβ substances that have been detected 
in the cores of Aβ plaques (see Section 7). One pos-
sibility is that these vesicles originate from intracel-
lular multivesicular bodies, which have been shown 
experimentally to be an important site of APP/Aβ 
biology [196-201]. In this regard, vesicular struc-
tures ranging from 50 to 300nm in diameter have 
been reported among the amyloid fibrils in a cell 
culture model of Aβ amyloid deposition [202]. 
The center of the compact core in some Aβ-
amyloid plaques is refractory to Aβ-
immunostaining (Figure 14), even though it is posi-
tive for the amyloid-selective dyes Thioflavin-S and 
Congo red [203]. Ultrastructural analysis indicates 
that the material in the center of fully developed 
plaques often has a more granular, amorphous 
appearance (Figure 13) than the obvious fibrils in 
the mantle of the core and in the periphery.  
 
Figure 10. Neurofibrillary tangles in the cortex of an AD patient 
immunostained with an antibody to Aβ40. When present, this 
colocalization occurs mostly on extracellular ('ghost') tangles. 
Nissl counterstain. Bar = 50μm. 
 
Classical Aβ-amyloid plaques are often as-
cribed special relevance to neurodegeneration [1, 
204], as they are much more likely to involve neu-
ritic malformation and reactive gliosis than are the 
diffuse deposits [133]. In this regard, it is notewor-
thy that cognitively normal elderly subjects with 
abundant Aβ plaques tend to have mostly diffuse 
plaques [1] with few neurites and little glial reactiv-
ity [139]. However, as noted above, there are rare 
cases of advanced AD in which classical plaques or 
dense-cored plaques are infrequent [90-93], sug-
gesting that amyloid per se is not essential to the
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Figure 11. Aβ deposits in white matter of an AD patient comprise clusters of small puncta and filamentous bundles. Left: Light-
micrograph of a cluster immunolabeled with antibody 4G8 (Nissl counterstain). Right, electron micrograph of a punctum immuno-
labeled with antibody 4G8 (black dots are gold particles bound to the secondary antibody). Bars = 20μm (left) and 200nm (right). 
 
 
Figure 12. Ultrastructure of fibrillar Aβ in the plaque corona (left) and core (right) in an AD patient. Bar = 500nm for both images. 
 
 
development of dementia. A similar situation holds 
for prion diseases, all of which are linked to the 
misfolding and self-assembly of PrP [205, 206]; in 
some prionoses (such as Gerstmann-Sträussler-
Scheinker syndrome and new-variant Creutzfeldt-
Jakob disease), PrP-amyloid plaques can be numer-
ous, whereas in others, little if any amyloid is pre-
sent [127]. In these instances, oligomeric species of 
the proteins may have particular importance [20], 
although this has not been definitely established. 
A small proportion of Aβ-amyloid plaques lack 
the outer corona and have few or no neurites; 
these relatively plain structures have been thought 
to represent an end-stage in the evolution of 
plaques, and so were dubbed ‘burned out’ plaques 
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[143, 178]. Based on their apparent sequential ap-
pear- 
 
Figure 13. High-magnification electron micrograph of a portion 
of the core of an Aβ-amyloid plaque in an AD patient. The 
fibrillarity of the material is less evident than in more periph-
eral zones. Unidentified particles (2 are marked by arrows) of 
various sizes and densities are interspersed among the amyloid 




Figure 14. Aβ plaque with an antibody-refractory central core 
in an AD patient. Antibody 6E10; Nissl counterstain. Bar = 
20μm. 
 
ance in the AD brain, a progression has been pro-
posed in which plaques originate as diffuse (‘primi-
tive’ or ‘immature’) deposits that evolve into classi-
cal (or ‘mature’) Aβ plaques and then finally into 
burned-out plaques [143].11 While longitudinal 
studies in mouse models of cerebral Aβ accumula-
tion have begun to shed light on the time-course of 
plaque development (see Section 10.2), the order 
of events in the human brain is still speculative 
[207].  
Biochemical determination of the age of Aβ 
deposits indicates that the amyloid core is older 
than the diffuse Aβ in the corona and in diffuse 
plaques [208, 209]. Armstrong [173] has suggested 
that the major plaque types mostly arise inde-
pendently, rather than in an evolutionary progres-
sion. In any case, the transformation of diffuse 
plaques into compact amyloid might not be an in-
evitable occurrence; for instance, it appears that 
diffuse Aβ deposits such as the lake-like cloud of Aβ 
in the subicular complex (Figure 9) do not progress 
into dense masses of amyloid, and this may be true 
also for cotton-wool plaques in AD cases with cer-
tain presenilin-1 mutations [90, 91, 93]. 
Finally, it should be emphasized that the rela-
tive pathogenicity of the many different Aβ plaque 
types in the aging human brain remains ambiguous. 
It is fairly certain that reactive gliosis/inflammation 
and the local disruption of neuronal processes in 
classical Aβ plaques are deleterious to brain func-
tion (see Section 6), but it is likely that oligomeric 
agents are the more directly injurious manifesta-
tion of misfolded proteins (see Section 1.1). In fact, 
while the plaques themselves are indicative of a 
pathogenic molecular process, in and of themselves 
they may be relatively benign or even protective 
[210, 211], at least when inflammation and sur-
rounding oligomers are negligible (see Sections 1.1 
and 6). 
5.2 Aβ strains 
In AD, the diverse morphological attributes of 
plaques might reflect, in addition to the local tissue 
organization, the variable truncation, folding, and 
molecular architecture of Aβ [212, 213]. These var-
iants are referred to as proteopathic strains, a bio-
logical concept that was adopted by the spongi-
form encephalopathy community to explain the 
alternative disease phenotypes resulting from prion 
                                                          
11 Diffuse plaques have long been considered an early stage in plaque 
formation (see, e.g., Critchley [1929] [reference 116]). 
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infections [214, 215]. At the molecular level, the 
formation and propagation of Aβ aggregates (as 
well as the proteins involved in several other pro-
teopathies [216]), constitute a mechanism that is 
fundamentally similar to that of prions [217, 218] 
(see Section 9).  
The capacity to spawn distinct strains is con-
sidered to be a shared property of proteins that are 
prone to misfolding and self-assembly [56, 59, 219]. 
In vitro, a given protein can create morphologically 
diverse amyloid fibrils under different environmen-
tal influences, for example temperature, pH, ionic 
strength, protein concentration [220, 221] and 
agitation [67, 222]. Strain properties can be con-
veyed to newly forming amyloid fibrils; in vivo, it is 
thought that proteopathic strains undergo confor-
mational selection by which the strain best suited 
to a given environment predominates [215, 220, 
223, 224]. Studies in genetically modified mouse 
models (which can be customized to make various 
types of Aβ) can shed light on the factors that gov-
ern alternative plaque morphologies in the living 
brain [225].  
The generation of Aβ strains is influenced by char-
acteristics of the aggregating Aβ such as mutations, 
truncations and chemical modifications (see Sec-
tions 1 and 7). Aβ forms distinct structural strains in 
different subtypes of AD [226-231]. Investigations 
 
 
Figure 15. Fluorescence-immunolabeled dyshoric cerebral Aβ-
amyloid angiopathy (red; antibody R398) and tau-
immunoreactive neurites (green; antibody CP13) in the cortex 
of an AD patient. Bar = 50μm. 
of the molecular configuration of Aβ fibrils in vitro 
have yielded insights into potential determinants of 
Aβ strains (see, e.g., [228, 232-235]), but cryo-
electron microscopic analysis of meningovascular 
Aβ-amyloid indicates that Aβ-CAA fibrils formed in 
vivo, though polymorphic, differ in important ways 
from those formed in vitro [66]. A similar analytic 
comparison of Aβ fibrils from plaques in the brain 
parenchyma and CAA could help to explain the 
inconsistent co-presence of plaques and amyloid 
angiopathy in AD. 
5.3 Cerebral Aβ-amyloid angiopathy (Aβ-CAA) 
Several different proteins can form CAA in dif-
ferent disorders, but Aβ is the most common 
source of CAA in the elderly [236]. Aβ accumulates 
in the vascular wall and perivascular zone in cases 
of primary Aβ-CAA involving mutations in the gene 
for APP [21, 237-240] and - to varying degrees - in 
nearly all cases of AD [241-244]. AD and Aβ-CAA 
share many genetic risk factors, and like Aβ 
plaques, idiopathic Aβ-CAA sometimes is present in 
the nondemented elderly [240, 241]. CAA is a sig-
nificant risk factor for lobar hemorrhage [236, 245], 
particularly in individuals with hypertension [246].  
In end-stage AD, the amount of Aβ-CAA varies 
widely, even in the presence of copious plaques 
[247], although the severity of Aβ-CAA tends to 
increase with increasing plaque load [21]. Further-
more, in some instances, Aβ-CAA can emerge in the 
absence or near absence of Aβ plaques, notably in 
an autosomal dominant form of Aβ-CAA known as 
hereditary cerebral hemorrhage with amyloidosis 
(Dutch type) (HCHWA-D) [239, 248, 249]. There is 
evidence for some diffuse parenchymal Aβ deposi-
tion [250, 251] and cognitive decline [238, 252] in 
these cases, but the clinical phenotype probably 
reflects the vascular pathology more than an AD-
like disorder in which plaques and tangles are 
abundant [253]. Cognitive dysfunction [254-258] 
and neurodegenerative changes [259] also have 
been associated with idiopathic Aβ-CAA.  
In approximately 25% of end-stage AD pa-
tients, Aβ-CAA affecting large vessels is considered 
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to be severe (arterioles are more often afflicted 
than are veins); capillary Aβ-CAA is less common, 
being severe in approximately 10% of cases [247]. 
In advanced Aβ-CAA, the amyloid often extends 
through the tunica adventitia and into the sur-
rounding parenchyma, where it is pervaded by tau-
immunoreactive abnormal neurites [25, 260, 261] 
(Figure 15). For unknown reasons, in regions of the 
neocortex where capillary Aβ-CAA is focally abun-
dant, Aβ plaques are relatively scarce [25, 247, 
262]. 
In the early stages of large-vessel Aβ-CAA, 
Aβ42 is more commonly present than is Aβ40 
[263], but in later stages Aβ40 predominates [263, 
264]. Capillary Aβ-CAA, however, more often is 
positive for Aβ42 than for Aβ40 [263]. It has been 
suggested that the deposition of Aβ in capillaries 
transpires by a different mechanism than that in 
large vessels and Aβ plaques [25, 26]. Quantitative 
spatial analysis has largely refuted the hypothesis 
that cerebral capillaries are the nidus of Aβ plaque 
formation [265]. Interestingly, ‘coarse-grain’ 
plaques, a special type of lesion (see Section 5.1), 
are more common in cases with abundant Aβ-CAA, 
particularly capillary Aβ-CAA [179].  
Aβ-CAA, like Aβ-plaques, is associated with re-
active gliosis and a perivascular inflammatory re-
sponse [240, 260], although the presence of frank 
perivascular inflammation is inconsistent [25, 266]. 
Aβ-amyloid plaques are occasionally confluent with 
Aβ-CAA (‘juxtavascular plaques’; Figure 16), but the 
etiologic relationship between these merged le-
sions is uncertain. 
 
 
Figure 16. Juxtavascular Aβ-plaque (arrow) in the cortex of an 
AD patient. Antibody 4G8, Nissl counterstain. Bar = 20μm. 
 
Various genetic, biochemical and pathophysio-
logic factors appear to influence how the misfold-
ing and aggregation of the same protein - Aβ - can 
lead to two different phenotypic presentations - 
parenchymal plaques and vascular amyloid [21]. 
While many auxiliary molecules are present in both 
Aβ plaques and Aβ-CAA, some are not shared by 
the two lesions [267]. Thus, Aβ-CAA and Aβ plaques 
likely result from at least partially distinct ontoge-
netic pathways [21] (in this regard, it is noteworthy 
that the disappearance of plaques in Alzheimer 
patients immunized against Aβ is accompanied by a 
[possibly transient] increase in Aβ-CAA, suggesting 
a transfer of Aβ from the parenchyma to the walls 
of blood vessels [268]). For in depth reviews of 
CAA, see [21, 236, 237, 240, 241, 260, 269]. 
6. Cellular components of Aβ plaques 
The main cellular elements - neuronal pro-
cesses and glial cells - in classical plaques were 
well-documented by pioneering investigators in the 
field (see [116]),12 although the nature of their in-
volvement, and their functional relationship to the 
core, have been a persistent matter of speculation 
[207]. Diffuse deposits of Aβ mostly lack obvious 
changes in local neurons and glial cells, whereas 
these cells are conspicuously altered in classical Aβ 
plaques. Since classical plaques are especially nu-
merous in most cases of late-stage AD, the associ-
ated abnormal neurites and activated glial cells 
probably contribute to the disturbance of brain 
function by the plaques [133]. 
6.1. Abnormal neurites 
In advanced AD, many Aβ plaques are deco-
rated with an impressive profusion of dysmorphic 
neurites (Figures 1, 4, 17). Both axons and den-
drites contribute neurites to plaques [207, 270]. 
Although most swollen neurites have been 
                                                          
12 Early descriptions of plaques included drawings that enabled the 
artist to clearly depict all cellular elements throughout the depth of the 
tissue sections in a way that photomicrography, still in its infancy, 
could not. The result was sometimes striking images that have been 
difficult to surpass in the century-plus since (see, e.g., the fine 
reproductions in DeFelipe [2010] [reference 510]). 
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Figure 17. Abnormal neurites associated with cortical Aβ plaques in two AD patients. Left: immunostain for neurofilament-H (antibody 
SMI31) with a Nissl counterstain; right, immunostain for a conformational epitope on tau filaments (antibody MC1). The presence of 
aberrant neurites that are immunoreactive for these antigens in plaques is variable. Bar = 25μm (right) and 50μm (left). 
 
reported to be axonal in origin [138, 178, 207], a 
quantitative analysis of plaques in humans using 
axon- and dendrite-specific markers is needed to 
establish the relative involvement of these neu-
ronal processes. Tortuous, atypical neurites that 
are not spatially associated with plaques are fairly 
common in the aging brain [139], but neuritic pa-
thology is particularly evident in many Aβ-amyloid 
plaques. By disrupting the structure and trajectory 
of neuronal processes, Aβ plaques are thought to 
interfere with the connectivity and network func-
tionality of the brain [38].  
Abnormal neurites are heterogeneous in size, 
shape and content. Ultrastructurally, plaque-
associated neurites may contain any of a number of 
inclusions, including, in addition to paired helical 
filaments, profuse mitochondria, various dense 
bodies, membranes, and multivesicular profiles 
[139, 178] (Figure 18). The mitochondria appear to 
be in different stages of degeneration, and they 
have been hypothesized to be a source of the Aβ-
amyloid in plaques [207], as have multivesicular 
bodies [199, 271, 272]. The cytoskeleton is disrupt-
ed in swollen neurites [273], and studies of mouse 
models found that neuritic calcium (Ca2+) homeo-
stasis [274] and autophagy [275] are dysregulated 
in them.  
Dickson [139] divided abnormal neurites into 
paired helical filament (PHF)-type neurites, which 
are characteristic of advanced AD, and dystrophic-
type neurites, which are relatively more frequent in 
the plaques found in aged, non-demented subjects 
(and in animal models, in which PHFs per se are 
rare or absent [165]; see Section 10). Dickson also 
notes, however, that many neurites have the prop-
erties of both types, and that abnormal neurites 
tend to arise from axons or dendrites that just hap-
pen to be in the vicinity of the plaque [139]. This is 
likely to be a general rule for the presence of spe-
cific types of neurites in plaques, including those 
containing markers for diverse neurotransmitters 
(see below) and, e.g., the alpha-synuclein-positive 
neurites in Aβ plaques that are sometimes co-




Figure 18. Abnormal neurite (top) containing organelles 
/debris adjacent to fibrillar amyloid (bottom) in the plaque 
corona of a patient with AD. Bar = 500nm. 
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Histochemically, lysosomal enzyme activity is 
pronounced in dystrophic neurites, as is histochem-
ical reactivity for APP and markers of degeneration 
such as chromogranin-A and ubiquitin [139]. The 
chemical variability of neurites may reflect, in addi-
tion to the neurons of origin, their stage of devel-
opment and their response to injury or stress [277]. 
Several early researchers, including Fischer [117] 
and Ramon y Cajal (see [278]), thought that the 
swollen neurites in plaques represented an attempt 
by the neuronal processes to sprout. Since then, 
multiple growth-promoting factors have been de-
tected in these neurites [278, 279], and Aβ deposits 
have been shown experimentally to induce axonal 
sprouting in the mouse brain [280]. Considered as a 
whole, these observations indicate the presence of 
both degenerative and regenerative mechanisms in 
the aberrant neuronal processes that are associat-
ed with Aβ plaques [133, 279].  
Analyses of Aβ plaques in humans and aged 
nonhuman primates found that many different 
neurotransmitter systems contribute anomalous 
neurites to plaques [281-287], and that an individ-
ual plaque can contain neurites from multiple 
sources [288, 289]. These studies cast doubt on the 
hypothesis [290] that plaques emerge from the 
regression of neurites from a specific transmitter 
system, in particular the acetylcholinergic neurons 
of the basal forebrain [141]. Rather, they highlight 
the probable role of a common catalyst (e.g., mis-
folded Aβ and/or reactive glia) in driving neuritic 
dystrophy [139, 289, 291]. Indeed, the influential 
model proposed by Wisniewski and Terry [178] (see 
also [81]) that posited neuritic abnormalities in 
general as the initial stage of plaque ontogeny now 
seems untenable, especially in light of genetic find-
ings implicating Aβ as the prime mover in the path-
ogenesis of AD [9, 22, 44, 45, 212]. Even so, dys-
morphic neurites do influence the pathologic 
plaque milieu [207], and it is possible that, by re-
leasing Aβ into the extracellular space, they con-
tribute to the growth of plaques [272]. In addition, 
neuritic Aβ plaques are generally more strongly 
associated with dementia than are diffuse plaques 
[1, 133, 204]. Finally, the loss of synapses correlates 
strongly with the degree of dementia in AD [292-
295]; synaptic pathology is especially evident in the 
immediate vicinity of Aβ plaques (see [296, 297], 
possibly owing to increased oligomeric Aβ in this 
region [297]. 
6.2 Glial cells 
Of the many genetic risk factors for AD [298], 
two of the most potent variant genes - APOE 
(apolipoprotein E) and TREM2 (triggering receptor 
expressed on myeloid cells-2) - are highly expressed 
in glial cells [115], as are several other AD-
associated genes [299-301]. Astrocytes and micro-
glia are protean and interactive components of the 
homeostatic intrinsic immune system in the brain 
 
 
Figure 19. Reactive astrocytes (left; antibody to GFAP) and microglia (right; antibody to IBA1) in cortical Aβ plaques of two AD patients. 
Despite some overlap of the two cell types within plaques, astrocytic somata tend to be more peripherally located than are microglial 
somata. Bar = 20μm for both panels. 
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and spinal cord [299, 302, 303]. Histologic, genetic, 
biochemical and physiological findings strongly 
implicate them in the pathogenesis of AD [111-115, 
299, 303-310] (Figure 19). Microglia and astrocytes 
do not operate independently of one another, but 
rather jointly influence Aβ processing and plaque 
biology [311, 312]. In the vicinity of Aβ-amyloid, 
these glial cells together form a partially integrated 
‘reactive glial net’ [313] that, while considered to 
be an attempt to shield nearby neurons from Aβ 
aggregates [314], ultimately engenders a neurotox-
ic inflammatory microenvironment [313].  
Inflammation is both a risk factor for, and a 
result of, the deposition of Aβ in the brain [45, 
315]. The recruitment and activation of glial cells by 
Aβ plaques has been likened to a local inflammato-
ry reaction to a foreign body [138, 139], although 
glia contribute to the pathobiology of plaques in 
complex ways [299, 302, 305, 309, 312, 316-318]. 
Mouse models have enabled a dynamic view of 
glial function and the general biology of plaques, 
whereas the genetic and physiologic analysis of glia 
in human AD is much less advanced [299]. Even 
given the caveat that glia differ in humans com-
pared to other species [316, 319, 320], mice have 
furnished unique insights into glial functionality in 
the living brain [304, 316, 321-324]. A growing lit-
erature underscores the ability of both microglia 
and astrocytes to adopt different physiologic states 
that influence how they contribute - positively or 
negatively - to AD (see, e.g., [299, 303, 306]). Cur-
rent views of glial cells thus emphasize their dual 
role in the pathobiology of AD: they participate in 
the clearance of aberrant Aβ and other debris, but 
they also can secrete a variety of inflammation- and 
cell-stress-related molecules [304, 325, 326]. Much 
contemporary research seeks to define and disen-
tangle these intricate and seemingly incompatible 
mechanisms.  
6.2.1 Microglia 
Activated microglia are intimately associated 
with the fibrillar Aβ in classical Aβ plaques [139, 
327-330] (Figure 20). They occupy much of the 
space between the plaque core and outer corona, 
and their processes interdigitate with the bundles 
of amyloid [311, 327]. The discovery that loss of 
function mutations in TREM2 are a strong risk fac-
tor for AD has heightened interest in the role of 
microglia in neurodegeneration [299, 306]. TREM2 
is a cell-surface immune receptor on many myeloid 
cells, including microglia, which exclusively express 
TREM2 in the brain [306]. The production of TREM2 
is increased in AD [331], and it mediates the activa-
tion and responsiveness of microglia to Aβ-amyloid 
plaques [332].  
Microglia have been thought to either phago-
cytose [139] or produce [311] multimeric Aβ, and 
their functional variability makes both actions con-
ceivable, depending on the circumstances. 
On the one hand, there is evidence that mi-
croglia normally impede the generation of Aβ 
plaques; inhibition of microglial functionality in 
mice was found to increase plaque load [333, 334], 
and microglia contribute to the clearance of dense-
core plaques following anti-Aβ immunization ther-
apy [335] (see also the analysis of immunized hu-
mans by Nicoll and colleagues [336]). Additionally, 
studies in mice indicate that TREM2 signaling trans-
forms homeostatic microglia into disease-
associated microglia (DAM), in which state they 
phagocytose Aβ in plaques [306, 337]. Impeding 
TREM2 functionality in microglia reduces the bind-
ing of ApoE to Aβ-amyloid in plaques and augments 
the seeded propagation of Aβ-amyloid [338]. (Ge-
netic knockout of TREM2 also promotes the seeded 
aggregation and spread of tau in neuritic Aβ 
plaques [339]).  
On the other hand, ultrastructural [311, 340, 
341] and experimental [342] investigations have 
suggested that microglia can generate Aβ-amyloid 
fibrils. In support of this hypothesis, sustained 
pharmacologic reduction of microglia significantly 
diminished Aβ plaque load in a transgenic mouse 
model [343].  
The ability of microglia to assume multiple 
phenotypic states underscores the complexity of 
their participation in the biology of Aβ plaques 
[299, 300, 305, 344-346]; they contribute to normal 
brain homeostasis, but they also have injurious 
properties, particularly when activated [299, 300]. 
In mice, microglia have been found to exhibit a 
range of activation states, each of which involves 
the expression of distinct gene modules [299]. Mi-
croglia become activated in the presence of 
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Figure 20. Electron micrographs of a microglial cell in an Aβ-amyloid plaque of an AD patient. The white box in the image on the left 
denotes the region at higher magnification on the right. The fibrillar bundles of Aβ interdigitate with the microglial soma. Note that the 
microglial cytoplasm appears artifactually rarefied in this autopsy-derived tissue. Bar = 500 nm (right), 2.8μm (left). 
 
 
aggregated Aβ, and in this condition they can harm 
the brain both through the secretion of pro-
inflammatory agents and the elimination of synap-
ses [300]. To complicate matters further, a variety 
of microglial phenotypes are simultaneously pre-
sent within the same brain [345], and the involve-
ment of microglia in plaques differs as a function of 
age and disease stage [299]. Finally, while the dis-
covery of microglial risk factors for AD emerged 
from human genetic analyses [306], we know far 
more about microglia in rodent models than in 
human AD, and current evidence suggests that 
there are important differences that cannot be 
overlooked [299, 347-349]. These findings collec-
tively highlight the challenges presented by micro-
glia as therapeutic targets in AD. 
6.2.2 Astrocytes 
In the vicinity of many Aβ-amyloid plaques, as-
trocytes hypertrophy and increase their expression 
of glial fibrillary acidic protein (GFAP) [316] (Figure 
19). The degree of astrocytic hypertrophy sur-
rounding plaques, however, is inconsistent [317]. 
GFAP expression is a reasonably reliable index of 
astrocytic reactivity, but GFAP is not detectable in 
many healthy astrocytes, and its expression varies 
in different parts of the brain, in different animal 
species, and as a function of age.13  
Compared to microglia, astrocytic somata 
tend to localize more peripherally to the aggregat-
ed Aβ in plaques [175, 302, 311, 313, 327, 330], 
whence their processes penetrate and to some 
extent encapsulate the plaques (Figure 19). Despite 
their tendency to partially segregate, astrocytes 
and microglia show some spatial overlap, and phys-
ical and chemical interactions between them help 
to define the inflammatory state of plaques [304]. 
Activated astrocytes promote the inflammatory 
milieu around plaques through the generation of 
pro-inflammatory substances, including cyto-
kines/chemokines, activation of the complement 
cascade, and reactive nitrogen and oxygen species 
[316].  
As in the case of microglia, the role of astro-
cytes in neurodegeneration is complicated by their 
variable and sometimes paradoxical phenotypes 
[317]. In AD, astrocytes can both gain a toxic func-
tion and lose their normal physiologic function 
[316, 350, 351]. Astrocytes have been shown ex-
perimentally to take up and degrade Aβ [315]. They 
                                                          
13 The authors note that the findings should be interpreted cautiously 
in light of the pitfalls associated with histochemical methods (Garwood 
et al. [2017] [reference 316]). This advice applies to histologic analyses 
in general, as methods and interpretations can vary among 
laboratories (e.g., Alafuzoff et al. [2008] [reference 511]). 
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also are capable of expressing Aβ [352], and astro-
cytes containing ample Aβ are present in the Alz-
heimeric brain [186, 316, 353, 354] (Figure 8). In 
addition, the extent of peri-plaque reactive astrocy-
tosis is positively correlated with cognitive status in 
aged subjects, and their abundance is reduced in 
persons expressing apolipoprotein E4, a major risk 
factor for AD [316].  
In summary, research on microglia and astro-
cytes has disclosed the extraordinary malleability of 
these glial cells, the complexity of their involve-
ment in plaques, and thus the attendant difficulties 
in targeting them therapeutically. Interventions 
that modulate the activity of glia could either pro-
mote or hinder disease progression, depending on 
the state of the cells in different brain areas, their 
relative abundance, and the timing of therapeutic 
delivery in the protracted course of AD. Neverthe-
less, the obvious importance of microglia and as-
trocytes in the pathobiology of AD justifies contin-
ued efforts to decipher the mechanisms by which 
they interact with Aβ and with the other cellular 
components of plaques. For additional reviews of 
microglia and astrocytes in aging and AD, see [312, 
355-357]. 
6.2.3 Oligodendrocytes 
Compared to microglia and astrocytes, oli-
godendrocytes have been less studied in AD [358]. 
Their involvement in plaques has long been debat-
ed (see, e.g., the contrasting views of Critchley 
[116] and Ferraro [118]: ‘Oligodendroglia apparent-
ly does not participate in the structure of plaques’ 
[Critchley, 1929]; ‘It is certain, then, that both oli-
godendroglia and microglia cells are usual compo-
nents of senile plaques’ [Ferraro, 1931]). Soniat 
contended that oligodendrocytes are not integral 
to the formation of plaques, but rather, when pre-
sent, their presence is purely coincidental [119]. A 
recent analysis, however, has revealed oligoden-
drocyte progenitor cells in Aβ plaques that become 
senescent and pro-inflammatory, in which state 
they are thought to augment the pathogenicity of 
aberrant Aβ [359]. More work on oligodendrocytes 
in association with Aβ plaques is clearly needed. 
 
7. The broader biochemistry of Aβ in 
plaques 
The number of molecules that have been 
linked in some way to Aβ plaques is considerable 
(see, e.g., [139, 175, 278, 279, 360-364]), creating 
fertile ground for hypotheses on both the origin of 
plaques and the nature of AD. Along with the many 
substances directly associated with neurons and 
glia, aggregated Aβ itself is rich in accompanying 
molecules. Amyloid P component is present in dif-
ferent types of amyloid throughout the body [6, 
365], including Aβ plaques [364, 366, 367]. Other 
molecules that have been reported to directly co-
localize with at least some Aβ deposits include pro-
teoglycans [6, 364, 368, 369], complement proteins 
[370-373], apolipoprotein E [374, 375], alpha-1 
antichymotrypsin [376] and advanced glycation end 
products [377, 378], along with lipids, metal ions, 
reactive oxygen species and nucleic acids (see 
Stewart and Radford [364]). How Aβ-linked sub-
stances might be involved in the pathobiology of 
plaques is attracting increasing attention. For in-
stance, a study in mice found that Aβ bound to 
nucleic acids acts as an immune signal, stimulating 
an antiviral response in microglia and astrocytes 
that instigates the complement-mediated elimina-
tion of local synapses [379].  
The plaque-associated proteome can be inter-
rogated by laser-microdissection of Aβ plaques 
followed by mass-spectrometric analysis [380-385]. 
These studies have identified numerous proteins 
that are enriched in plaques, though whether they 
are directly associated with multimeric Aβ or with 
the cellular constituents is sometimes undefined. It 
has been proposed that plaques mature through 
three biochemical stages within which the toxicity 
of the aggregates may differ; in stage 1, the aggre-
gates lack both pyroglutamation at residue 3 
(AβNp3E) and phosphorylation at residue 8 
(pSer8Aβ); in stage 2, AβNp3E appears, and in stage 
3, both AβNp3E and pSer8Aβ are present [19, 386]. 
Post-translational chemical modifications of Aβ can 
influence the aggregation of the protein along with 
the type of deposit that is formed in the brain [19, 
387-391], but the mechanisms are, in many cases, 
still uncertain. 
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8. Microbes and plaques 
The notion that microbes might participate in 
the genesis of plaques has been considered at least 
since the early 20th century.14 Fischer likened ma-
ture plaques to actinomyces ‘Drusen’, although he 
noted that they were negative for multiple bacteri-
al stains [117]. Critchley remarked in 1929 that the 
microbial origin hypothesis had failed to gain trac-
tion [116]. Despite more recent claims that senile 
plaques in AD ‘are made up by spirochetes’ [392], 
there is still no credible evidence that Aβ plaques 
are primarily collections of microbes or their re-
mains.  
That said, there is fairly compelling evidence 
that certain microbial infections are risk factors for 
AD [393-395]. Perhaps the best evidence indicates 
that some herpesviridae increase the probability of 
developing AD [394, 396, 397]. Over 15 different 
microbes have been linked to AD by various re-
searchers [398], but in many instances the findings 
are weak or contradictory (see, e.g., [399, 400]). In 
addition, it is important to distinguish cases of de-
mentia in general (for which there are over 50 dif-
ferent causes [330]) from cases of dementia specif-
ically due to the pathology of AD (as defined by 
Jack and colleagues [109]). It is fair to say that no 
known infectious agent is universally and exclusive-
ly associated with AD [395], but it seems likely that 
any of several types of brain infection (including 
chronic infection and/or reactivation of resident 
microbes) can accelerate plaque formation and the 
pathogenesis of AD [394, 395, 401, 402]. In other 
words, at least in some instances the development 
of plaques may represent a non-specific response 
to various infectious organisms.  
Aggregated Aβ has antimicrobial properties 
[395, 403, 404], and some microbial antigens have 
been reported in Aβ plaques [392, 405], but a sys-
tematic and comprehensive survey of microbial 
markers in different types of plaques and Aβ-CAA 
throughout the central nervous system has not 
been reported. APP-transgenic mice raised in a 
germ-free environment develop some Aβ plaques 
as they age, albeit fewer than mice raised in normal 
caging [406]. With the caveat that the mice strongly 
                                                          
14 I use the term ‘microbe’ here to include both conventional (living) 
microorganisms and viruses (but not prions). 
overexpress transgenic Aβ, the findings suggest 
that infection is not required for plaque formation, 
but that it can trigger and/or accelerate the pro-
cess. The role of infection in the causation of Aβ 
plaques and as a risk factor for AD is an intriguing 
topic with potential implications for prevention and 
therapy, but supporting evidence for a specific role 
of specific microbes in pathogenesis is needed. For 
a critical consideration of the state of the field, see 
[393]. 
9. The seeded induction of Aβ plaque 
formation 
The prion paradigm has become the dominant 
mechanistic explanation for the aberrant self-
assembly and propagation of misfolded proteins in 
the brain and elsewhere in the body [58, 205, 218, 
407-409]. At the molecular level, the prion para-
digm postulates that misfolded, β-sheet-rich pro-
teins aggregate into oligomeric/polymeric assem-
blies that can induce protein molecules of the same 
type to adopt a similar conformation. In this condi-
tion, the proteins tend to stick together, with the 
assemblies often (but not always) amassing into 
amyloid deposits.  
In the prion diseases, misfolded PrP self-
assembles into highly stable multimers that are 
transmissible from one organism to another - the 
first verified instance of an infectious protein parti-
cle (‘prion’) [410, 411]. Human prion diseases also 
originate spontaneously or as a result of mutations 
in the gene for PrP [412]. The pathological signa-
ture of the prion diseases varies considerably [127, 
128], but, as in AD, the universal feature of 
prionopathies is the accumulation of an abnormally 
folded protein - in this case PrP - in the nervous 
system.  
Systematic studies in transgenic mouse mod-
els expressing human APP have determined that Aβ 
plaque formation is driven by a molecular process 
that is indistinguishable from the mechanism by 
which prions instigate disease [217, 218, 413-415] 
(Figure 21). In this paradigm, brain extracts con-
taining aggregated Aβ are infused into the brains of 
susceptible mice, instigating Aβ plaque develop-
ment in a model-, dose- and time-dependent fash-
ion [218, 407]. Analyses of seeded aggregation in 
Free Neuropathology 1:31 (2020) Lary C. Walker 




experimental systems have demonstrated that Aβ 
seeds share key properties with prions: 1) they are 
protein-only agents that are resistant to destruc-
tion by heat and formaldehyde; 2) they incite the 
formation of cerebral Aβ plaques and Aβ-amyloid 
angiopathy when introduced into the brain or into 
the periphery; 3) they exist in multiple sizes; and 4) 
they can fold into different molecular variants re-
ferred to as proteopathic strains [212, 213, 217, 
218, 407] (see Section 5.2). The strain-like proper-
ties of Aβ deriving from different subtypes of AD 
can be partially transmitted to plaques via exoge-
nous seeding in mouse models [227, 230].  
 
 
Figure 21. Seeded Aβ deposition in the hippocampal formation 
of a TG2576 APP-transgenic mouse 5-months following unilat-
eral injection of dilute AD brain extract into one hemisphere 
(left). The contralateral hippocampus in the same tissue sec-
tion is on the right. Antibody 4G8; Bar = 100μm. 
 
These investigations highlight the prion-like 
seeded aggregation of Aβ as the propulsive mecha-
nism behind the formation of Aβ plaques. Since 
there is currently no evidence that AD or other 
cerebral proteopathies are infectious under ordi-
nary circumstances [416, 417], it is likely that 
plaques ordinarily arise endogenously with the 
stochastic emergence, persistence and spread of 
Aβ seeds. This process can be advanced by various 
environmental and endogenous risk factors that 
influence the likelihood that Aβ will misfold and 
propagate in the brain [45].  
Under extraordinary circumstances, however, 
Aβ plaques and Aβ-CAA can be instigated by exog-
enous Aβ seeds in humans [417]. Treatment of 
young people with growth hormone derived from 
cadaveric human pituitary glands, beginning in the 
late 1950s, resulted unexpectedly in the develop-
ment of prion disease (Creutzfeldt-Jakob disease) 
many years later [418, 419]. The apparent cause 
was the presence of infectious prions in the prepa-
rations, probably because the large batches of pitu-
itaries that were homogenized for extraction of 
growth hormone contained some glands from de-
cedents with prion disease. Researchers in England 
later found that both Aβ plaques and Aβ-CAA were 
much more common in human growth hormone-
treated subjects than in non-treated controls [420]. 
Furthermore, Aβ deposition was precipitated both 
in growth hormone recipients dying with [420] or 
without [421] Creutzfeldt-Jakob disease. An in-
crease in Aβ-proteopathy also has been reported in 
a subset of people who had received cadaveric 
dura mater transplants [422, 423].  
The most parsimonious explanation for these 
findings is that some batches of therapeutic growth 
hormone and dura mater were tainted by Aβ seeds 
that were present in the tissues taken from donors 
with AD (or incipient AD) [417]. This possibility is 
reinforced by the demonstrable presence of aggre-
gated Aβ in some pituitary glands [424] and dura 
mater [425] from AD patients. Furthermore, Aβ 
was detected in archival samples of cadaveric hu-
man growth hormone [426], and stored hormone 
was shown to stimulate cerebral Aβ deposition 
when injected intracerebrally into APP-transgenic 
mice [427]. Interestingly, tauopathy was not appar-
ent in most of these cases (even though some ab-
normal tau is present in Alzheimeric pituitaries), 
and no recipients of cadaveric growth hormone or 
dura mater have yet been found to develop full-
blown AD. Whether this will happen as the subjects 
age further remains to be determined. 
10. Aβ plaques in nonhuman species 
10.1 Native Aβ plaques 
Naturally occurring Aβ plaques and/or Aβ-CAA 
have been identified in aged animals of many spe-
cies, including such diverse creatures as woodpeck-
ers [428], bears [429-431], dogs [432-435], cats 
[436], camels [437] wolverines [438], and all spe-
cies of nonhuman primate examined to date [165, 
435, 439]. The mammalian mainstays of experi-
mental biology - rats and mice - do not normally 
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manifest plaques in old age, possibly owing to 3 
amino acid differences in the N-terminal segment 
of Aβ that render the protein less likely to aggre-
gate [440, 441].  
Most research on native Aβ plaques in non-
human species has focused on primates ranging 
from prosimians to monkeys and apes [439], work 
that has yielded insights into the pathobiology of 
the lesions [178, 439, 442-444]. Nonhuman pri-
mates express Aβ with the same sequence of ami-
no acids as in humans, and both diffuse and dense-
core Aβ plaques can be abundant in aged primates 
[439] (Figure 22). Some of the plaques include re-
active glial cells and dysmorphic neurites [444]. 
Mass-spectrometry has shown that post-
translational modifications of Aβ are similar in hu-
mans and squirrel monkeys (Saimiri sciureus), and 
by ELISA, the amount of Aβ in the nonhuman pri-
mate brain sometimes exceeds that in humans with 
AD [163]. 
Despite the presence of copious aberrant Aβ, 
no nonhuman species has yet been found to exhibit 
the full clinicopathologic phenotype of AD as it 
occurs in humans [165]. Specifically, a dementia-
like condition has not yet been identified, and 
tauopathy, though often present, is generally mild, 
even in the presence of profuse Aβ plaques. For 
unknown reasons, Aβ-CAA, especially capillary Aβ-
CAA, is more commonly present in nonhuman pri-
mates than in humans [439, 445, 446]. Although 
congophilic Aβ plaques occur, human-like classical 
plaques with an Aβ core, space, and outer corona 
(see Figure 1) are rare, if they can be found at all, in 
prosimians and monkeys (we cannot yet rule out 
such lesions in great apes, as relatively few have 
been examined in advanced old age). Surprisingly, 
there is little high-affinity binding of the Aβ-
amyloid-imaging agent Pittsburgh Compound-B 
(PiB) to Aβ plaques in nonhuman primates, suggest-
ing biochemical and/or conformational differences 
in the protein between humans and other primates 
[447].  
It is necessary to determine how differences in 
lifespan and environmental and genetic risk factors 
might influence the apparent species-specificity of 
AD and the Aβ-deposition phenotype. However, 
current evidence suggests that, despite similarities 
in the sequence, expression, modification, and 
deposition of Aβ, nonhuman primates lack the 
permissive connection between Aβ-proteopathy 
and tauopathy that is critical to the occurrence of 
AD in humans [165]. Clarifying the nature of this 
naturally occurring interruption of the Aβ cascade 
in nonhuman species could reveal new pathogenic 
pathways for therapeutic intervention in AD. 
 
 
Figure 22. Aβ deposition (left) in the superior temporal gyrus and a neuritic plaque (right) in the hippocampal formation of two aged 
rhesus monkeys (Macaca mulatta; 35 years and ~30 years, respectively). Left: Antibody 82E1 to the N-terminal segment of Aβ, Nissl 
counterstain; Right: Antibody 06-17 to phosphorylated neurofilaments. Bars = 200μm (left) and 25μm (right). The maximum known 
lifespan of rhesus monkeys is 44 years (see Stonebarger et al. [2020] [reference 512]). 
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Figure 23. Aβ plaques in an aged (28 months) Tg2576 APP-transgenic mouse. Diffuse deposits are black, and some dense deposits have 
a golden core (one in the frontal cortex is magnified at right). Campbell-Gallyas silver stain. Bars = 1mm (left) and 50μm (right). 
 
10.2 Aβ plaques in genetically modified animals 
Studies of naturally occurring plaques in vari-
ous species have shed some light on the lesions, 
but there was no practical model in which plaques 
could be experimentally investigated until the mid-
1990s. Then, transgenic mice were introduced that 
overexpress human APP with genetic mutations 
linked to AD [448-450]. With age, these APP-
transgenic mice deposit copious Aβ in the brain 
(Figure 23). They were followed by a wealth of ad-
ditional models in various mouse (and later rat) 
strains with diverse genetic alterations, transgene 
expression levels, and the expression or deletion of 
interacting molecules [451-453]; see Alzforum for a 
list of rodent models of AD-like pathology: 
https://www.alzforum.org/research-models/alzhei
mers-disease). Not surprisingly, the sundry genet-
ically modified animals exhibit many plaque (and 
CAA) phenotypes. No genetically modified rodent, 
including those with multiple modifications, has 
manifested fully AD-like Aβ plaques. As in nonhu-
man primates, the core-space-corona type of 
plaque is not typical of the transgenic rodent mod-
els. The plaques do, however, share several key 
features with those in humans; they exhibit a range 
of morphologies, many have bona fide amyloid 
cores, and they are invested by aberrant neurites 
and glial cells [452]. Tau abnormalities occur, but 
human-like neurofibrillary tangles have not yet 
been generated in rodents.  
Nonvertebrate transgenic animals such as fruit 
flies (Drosophila melanogaster) [454-456] and 
roundworms (Caenorhabditis elegans) [457, 458] 
have been developed to study the pathobiology of 
Aβ. These models can be useful for analyzing mo-
lecular mechanisms and for studying the early-
stage efficacy and toxicity of investigational agents, 
but no nonvertebrate model has yet generated Aβ 
plaques that remotely resemble those in humans. 
It is difficult to overstate the impact that the 
introduction of genetically modified animals has 
had on the course of research on the mechanisms 
underlying plaque formation and AD. For example, 
transgenic rodents were used to establish the prion 
paradigm as the pre-eminent theory of plaque on-
togeny and spread [217, 218, 407] (see Section 9), 
they are being used to probe the role of glial cells 
and neuritic dystrophy in plaque pathophysiology 
(see Section 6), and they are a vital tool in the pre-
clinical testing of new therapeutic and diagnostic 
strategies [452, 459-463]. For instance, whereas 
the first evidence that Aβ plaques and Aβ-CAA 
could be targeted by anti-Aβ antibodies in the living 
brain came from experiments in nonhuman pri-
mates [464], genetically modified mice enabled the 
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development of Aβ-immunization as a strategy for 
the prevention or treatment of AD [465].  
The application of longitudinal, in vivo-imaging 
studies in murine models has facilitated unique 
insights into the dynamics of Aβ plaques and their 
cellular constituents (e.g., [323, 324, 466-469]), as 
well as the response of plaques and Aβ-CAA to 
therapeutic intervention [451, 452, 470]. Currently, 
genetically modified nonhuman primates are being 
created with the hope that they will more com-
pletely recapitulate a human-like AD phenotype 
[471, 472], but no histopathologic findings have yet 
been reported. Despite the limitation that genet-
ically modified animals do not yet fully recapitulate 
AD, they will continue to play an important part in 
deciphering the pathobiology of Aβ plaques. 
11. Conclusions: Aβ plaques as a ther-
apeutic objective 
Aβ plaques are an obligatory component of 
the pathobiology of AD, and as such, strategies to 
reduce or neutralize plaques intersect with general 
strategies to prevent or treat AD. However, the 
value of plaques, in and of themselves, as thera-
peutic targets is uncertain. There is little question 
that Aβ plaques, especially in their more elaborate 
states, are deleterious to brain tissue; they disrupt 
neuronal processes and synapses, they can be a 
source of harmful Aβ-oligomers, and local glial cells 
create a toxic inflammatory environment. Thera-
peutically targeting plaques thus presents both 
opportunity and obstacles.  
First, given the long, pre-symptomatic emer-
gence and proliferation of Aβ plaques (and neurofi-
brillary tangles) in the brain [109, 473], as well as 
evidence of extensive brain damage by the time 
dementia sets in, early prevention is likely to be the 
most effective strategy for subduing AD [474, 475]. 
The promise of prevention is underscored by the 
protective effects of the A673T mutation in APP, 
which diminishes Aβ production throughout life 
and lowers the risk of AD [48]. Since the most ef-
fective preventive protocol should be initiated 
years, and possibly decades, before the predicted 
onset of dementia, testing for long-term safety and 
efficacy will be challenging. Additionally, it is not 
known when, in the course of life, therapy must 
begin to effectively prevent or delay AD.  
Second, it is possible that some, if not most, of 
the direct toxic influence of the Aβ is mediated by 
oligomeric Aβ rather than by fibrillar amyloid per 
se. Evidence that Aβ plaques can serve as a source 
of oligomers (Section 1.1) argues that some benefit 
can be achieved by reducing plaque burden and 
thus the accompanying oligomers. It is encouraging 
that several of the more promising antibodies cur-
rently in clinical trials for AD show activity against 
oligomeric Aβ [475, 476]. A recent study in mice 
indicates that the short-term neutralization of oli-
gomeric Aβ seeds early in life diminishes plaque 
formation as the animals age [477]. However, 
whether mitigating the production, seeding poten-
tial or toxicity of oligomeric Aβ will be beneficial in 
humans, either as a preventive or as a treatment 
for discernible dementia, remains to be deter-
mined. It is also important to consider the possibil-
ity that treatments that block Aβ-amyloid fibril 
assembly, or that disassemble plaques, might inad-
vertently increase the presence of toxic oligomers.  
Third, the inability of anti-Aβ immunothera-
pies to substantially impede dementia in sympto-
matic subjects, even when Aβ plaques are reduced 
in number [336, 476, 478, 479], suggests that the 
dis-integration of the cerebral connectome caused 
by plaques and tangles is pronounced and largely 
irreversible once dementia commences [9, 474]. 
Furthermore, tauopathy is an essential contributor 
to dementia that itself progresses by a prion-like 
mechanism [480, 481] that may be at least partly 
independent of Aβ-proteopathy [336]. Whether the 
alternative approach of lowering the inflammatory 
state associated with plaques will meaningfully 
improve behavior at this later stage of disease also 
has not been established.  
In short, once Aβ-amyloid plaques and 
tauopathy become widespread, especially in neo-
cortical regions [1], removing the plaques is unlike-
ly to significantly reverse the course of dementia. 
Even so, there is evidence that a reduction of 
tauopathy [336], and possibly some cognitive bene-
fit, can be achieved in symptomatic patients by 
anti-Aβ immunotherapy [476, 482-484]. Indeed, 
active immunization with AN1792, which targets 
both Aβ plaques and oligomers, resulted in a long-
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term decrease in all components of the plaques - 
aggregated Aβ, aberrant neurites, tauopathy, and 
focal gliopathy - along with improved indices of 
‘neuronal health’ [336]. Thus, notwithstanding the 
mostly disheartening outcome of therapeutic trials 
to date, current preclinical and clinical data indicate 
that the right anti-Aβ treatment, at the right time, 
has a good chance of delaying or preventing AD.  
Finally, it is imperative to remain vigilant to 
the impact of environmental factors and the mi-
crobiome [485, 486] on the risk of developing AD. 
For instance, if specific microbes are convincingly 
found to increase the risk of plaque formation and 
AD, early immunization against this infectious 
agent could be an effective preventive measure. It 
is important also to consider the possibility that 
interactions among genetic, microbiomic and/or 
environmental influences could raise disease risk 
well above the additive impact of individual risk 
factors.  
The search for disease-modifying therapies for 
AD is a broad and rapidly evolving endeavor that 
has been extensively reviewed (see, e.g., [9, 33, 
476, 479, 487-491]. In addition to small molecules, 
we have entered a phase in medicine in which bio-
logics such as antibodies [492, 493] and nucleic 
acid-based agents [494, 495] have unprecedented 
potential to treat neurodegenerative diseases. For 
well over a century, Aβ plaques have been recog-
nized as an important correlate of dementia in the 
aging brain. Revealing the mechanisms by which 
plaques arise, proliferate, and interact with mo-
lecular and cellular elements in the nervous system 
will continue to yield insights into both the ontoge-
ny and treatment of AD. 
12. Methods  
Tissue samples were collected from human 
subjects with end-stage AD (Figures 1-6, 8-20) and 
from aged nonhuman species with cerebral Aβ 
deposition (Figures 21-23). Postmortem collection 
of samples by the Emory University Goizueta Alz-
heimer’s Disease Research Center Brain Bank was 
approved by the Emory Institutional Review Board. 
Tissues from mice and monkeys were collected at 
Emory’s Yerkes National Primate Research Center 
in accordance with federal and institutional guide-
lines for the humane care and use of experimental 
animals. The Yerkes Center is fully accredited by 
AAALAC International. 
12.1. Immunohistochemistry 
For light-microscopy, tissue blocks were em-
bedded, sectioned at 8-10 μm thickness, and 
mounted onto glass slides for staining. The follow-
ing antibodies were used for immunohistochemis-
try: 4G8, mouse monoclonal antibody from Co-
vance (Princeton, NJ) raised against residues 17-24 
of Aβ peptide, with an epitope at residues 18-22 
[496]; 6E10, mouse monoclonal antibody from Co-
vance raised against residues 1-16 of the Aβ pep-
tide, with an epitope at residues 3-8 [496]; Rabbit 
polyclonal antibodies R361 and R398, kindly pro-
vided by Dr. Pankaj Mehta (Institute for Basic Re-
search on Developmental Disabilities, Staten Island, 
NY), were raised against synthetic Aβ32-40 and 
Aβ33-42, respectively [497]; 82E1, mouse mono-
clonal antibody raised against residues 1-16 of syn-
thetic Aβ [498], from IBL (Gunma, Japan); CP13, 
mouse monoclonal antibody kindly provided by Dr. 
Peter Davies (Feinstein Institutes for Medical Re-
search, Manhasset, NY), was raised against a syn-
thetic peptide representing the region around 
phosphorylated serine residue 202 on the tau pro-
tein [499]; MC1, mouse monoclonal antibody, also 
from Dr. Davies, was raised against Alz50-
immunopurified paired helical filaments and then 
epitope-mapped to similar conformation-specific 
regions as Alz50 [500]; anti-GFAP, purified immu-
noglobulin fraction of rabbit antiserum from Dako 
(Carpinteria, CA) (catalog No. Z0334), raised against 
GFAP isolated from cow spinal cord and purified by 
solid-phase absorption with human and cow serum 
proteins; anti-Iba1, rabbit polyclonal antibody from 
Wako (Osaka, Japan), raised against a synthetic 
peptide corresponding to the C-terminus of ionized 
calcium-binding adapter molecule 1 (Iba1), a 17-
kDa protein that is specifically expressed in macro-
phages/microglia and is upregulated during the 
activation of these cells [501, 502]; SMI-31, mouse 
monoclonal antibody raised against a phosphory-
lated epitope on the neurofilament heavy subunit 
(NF-H) [503] from BioLegend (San Diego, CA); and 
06-17, mouse monoclonal antibody to a phosphory-
lated epitope shared by the heavy and medium kDa 
neurofilament polypeptides (generous gift of Drs. 
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Ludwig and Nancy Sternberger, University of Mary-
land, Baltimore) [504, 505].  
Vectastain Elite kits (Vector Laboratories, 
Burlingame, CA) were used for ABC-based immu-
nodetection of antigen-antibody complexes accord-
ing to the manufacturer’s instructions, with dia-
minobenzidine (DAB) as coloring agent for images 
in Figures 1, 2, 5, 6, 8-11, 14, 16, 17, 19, 21, & 22. 
In most cases, a Nissl counterstain was applied 
after immunostaining, as noted. For dual fluores-
cence immunostaining (Figure 15), the section was 
incubated in mouse monoclonal antibody CP13 
(diluted in 2% normal goat serum) overnight at 4°C, 
rinsed, and then incubated for 90 minutes in Cy2-
conjugated anti-mouse secondary antibody (green; 
Jackson Labs, West Grove, PA). The section was 
rinsed thoroughly, incubated overnight in diluted 
rabbit polyclonal antibody R398 at 4°C, rinsed, and 
placed for 90 minutes in Rhodamine-Red-X goat 
anti-rabbit secondary antibody (Jackson Labs). For 
dual immunostaining by standard transillumination 
light microscopy (Figure 3), antibodies were se-
quentially applied as described above except that 
the polyclonal anti-Aβ antibodies R398+R361 were 
colored with DAB (brown), and the anti-tau mono-
clonal antibody CP13 was colored with VIP (purple; 
Vector Laboratories). Non-immune mouse IgG or 
rabbit sera were used in place of the primary anti-
bodies as negative controls.  
Tissues shown in Figures 1 (left) and 4 were 
stained with the Naoumenko-Feigin silver stain 
[506] followed by a periodic acid-Schiff (PAS) coun-
terstain. Figure 23 was stained with the Campbell-
Gallyas silver stain [507]. Light-microscopic photo-
micrographs were taken with a Leica DMLB or 
DMLS microscope (Wetzlar, Germany) and a SPOT 
FLEX (Diagnostic Instruments, Sterling Heights, MI) 
or Moticam 5+ (Motic, Hong Kong) digital camera.  
12.2. Electron microscopy 
For conventional ultrastructural analysis (Fig-
ures 12, 13, 18, 20), small blocks of cortex were 
sub-dissected from larger, autopsy-derived tissue 
blocks that had been immersion-fixed in 10% neu-
tral buffered formalin. The tissue samples were 
washed in phosphate buffer (0.1M, pH 7.4) and 
immersed in osmium tetroxide (1% in phosphate 
buffer) for 20 minutes. They were then rinsed in 
phosphate buffer and dehydrated in a graded se-
ries of ethanol and propylene oxide. Uranyl acetate 
(1%) was added to the 70% ethanol (35 minute 
immersion) to improve contrast in the electron 
microscope. The sections were then embedded in 
epoxy resin (Durcupan ACM; Fluka, Ft. Washington, 
PA) on microscope slides and heated for 48 hours 
at 60°C. Areas of interest were selected, excised 
from the slide and glued onto resin blocks. Ul-
trathin sections were cut with a Leica Ultracut T2 
(Nussloch, Germany), collected onto single-slot 
copper grids, and stained with lead citrate.  
For immunogold EM (Figure 11, right), sec-
tions were preincubated in PBS containing 5% non-
fat dry milk and then washed in Tris-buffered saline 
(TBS)-gelatin buffer (0.02 M Tris, 0.15 M NaCl, 1 
μl/ml fish gelatin, pH 7.6) to block nonspecific sites. 
Sections were then incubated for 48 hours at 4°C 
with antibody 4G8 diluted in PBS-BSA, rinsed in 
TBS-gelatin, and incubated for 2 hours at room 
temperature in gold-conjugated goat anti-mouse 
Fab’ fragments (dilution 1:100; Nanogold [Nano-
probes Inc., Yaphank, NY]). Gold particles were 
silver-enhanced with the HQ Silver kit (Nano-
probes). The tissue was then embedded and cut as 
described above. Thin sections were examined with 
a Zeiss EM10-C electron microscope (Oberkochen, 
Germany) and digital images were captured using a 
Dual View camera (Gatan Inc., Pleasanton, CA).  
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